A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor Xr On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193 Phase 1 COMPLETED

The purpose of this study is to demonstrate a lack of effect of venlafaxine (Effexor XR) on QTc intervals relative to time matched placebo in healthy volunteers

Details

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	54
Start date	2015-12
Completion	2016-07

Conditions

• Healthy Subjects

Interventions

• Venlafaxine
• Moxifloxacin
• Drug - placebo

Primary outcomes

• Postdose QTcF (Fridericia's correction) intervals — 0 to 24 hours

Countries

United States